Tricetin, a dietary flavonoid, suppresses benzo(a)pyrene‑induced human non‑small cell lung cancer bone metastasis

Hung,Jen‑Yu; Chang,Wei‑An; Tsai,Ying‑Ming; Hsu,Ya‑Ling; Chiang,Hung‑Hsing; Chou,Shah‑Hwa; Huang,Ming‑Shyan; Kuo,Po‑Lin

doi:10.3892/ijo.2015.2915

Tricetin, a dietary flavonoid, suppresses benzo(a)pyrene‑induced human non‑small cell lung cancer bone metastasis

Authors:
- Jen‑Yu Hung
- Wei‑An Chang
- Ying‑Ming Tsai
- Ya‑Ling Hsu
- Hung‑Hsing Chiang
- Shah‑Hwa Chou
- Ming‑Shyan Huang
- Po‑Lin Kuo
View Affiliations

Affiliations: School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C., Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Division of Chest Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C.
Published online on: March 4, 2015 https://doi.org/10.3892/ijo.2015.2915
Pages: 1985-1993

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This is the first study to demonstrate that benzo(a)pyrene (BaP) was able to enhance the production of parathyroid hormone‑related protein (PTHrP) by human non‑small cell lung cancer H460 cells. Such effect would further contribute to bone metastasis of lung cancer by increasing osteoclastogenesis. This study is also the first to reveal that tricetin (TCN), a flavonoid derivative found in Myrtaceae pollen and Eucalyptus honey, was able to reverse BaP‑mediated bone resorption activity of lung cancer cells. Human non‑small cell lung cancer H460 cells were treated with BaP to generate conditioned medium. When osteoblasts were cultured with BaP‑H460‑CM, their expression of osteoclastogenesis activator macrophage colony‑stimulating factor (M‑CSF) and receptor activator of nuclear factor κB ligand (RANKL) was increased. BaP‑H460‑CM reduced the production of osteoprotegerin (OPG), an osteoclastogenesis inhibitor, in osteoblasts. Osteoclastogenesis and bone resorption activity of H460 cells were increased by BaP‑H460‑CM. With BaP‑mediated PTHrP upregulation, IL‑8 secretion in H460 cells was increased contributing to human non‑small cell lung cancer‑mediated osteoclast differentiation and bone resorption. Moreover, TCN suppressed BaP‑mediated bone resorption. Therefore, TCN may be a novel agent for treatment of non‑small cell lung cancer patients with bone metastasis.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Zükin M: Epidermal growth factor receptor inhibitors in non-small cell lung cancer: Current status and future perspectives. Rev Assoc Med Bras. 58:263–268. 2012. View Article : Google Scholar : PubMed/NCBI
3	Kuo PL, Liao SH, Hung JY, Huang MS and Hsu YL: Micro-RNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein. Biochim Biophys Acta. 1830:3756–3766. 2013. View Article : Google Scholar : PubMed/NCBI
4	Al Husaini H, Wheatley-Price P, Clemons M and Shepherd FA: Prevention and management of bone metastases in lung cancer: A review. J Thorac Oncol. 4:251–259. 2009. View Article : Google Scholar : PubMed/NCBI
5	Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE and Coleman RE: Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 3:228–236. 2008. View Article : Google Scholar : PubMed/NCBI
6	Sterling JA, Edwards JR, Martin TJ and Mundy GR: Advances in the biology of bone metastasis: How the skeleton affects tumor behavior. Bone. 48:6–15. 2011. View Article : Google Scholar
7	Sims NA and Gooi JH: Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol. 19:444–451. 2008. View Article : Google Scholar : PubMed/NCBI
8	Miller RE, Jones JC, Tometsko M, Blake ML and Dougall WC: RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. J Thorac Oncol. 9:345–354. 2014. View Article : Google Scholar : PubMed/NCBI
9	Esposito M and Kang Y: Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther. 141:222–233. 2014. View Article : Google Scholar :
10	Phillips DH: Polycyclic aromatic hydrocarbons in the diet. Mutat Res. 443:139–147. 1999. View Article : Google Scholar : PubMed/NCBI
11	Anastasio A, Mercogliano R, Vollano L, Pepe T and Cortesi ML: Levels of benzo[a]pyrene (BaP) in ‘mozzarella di bufala campana’ cheese smoked according to different procedures. J Agric Food Chem. 52:4452–4455. 2004. View Article : Google Scholar : PubMed/NCBI
12	Domingo JL: Influence of cooking processes on the concentrations of toxic metals and various organic environmental pollutants in food: A review of the published literature. Crit Rev Food Sci Nutr. 51:29–37. 2011. View Article : Google Scholar : PubMed/NCBI
13	Guillén MD, Sopelana P and Partearroyo MA: Food as a source of polycyclic aromatic carcinogens. Rev Environ Health. 12:133–146. 1997. View Article : Google Scholar : PubMed/NCBI
14	Rota M, Bosetti C, Boccia S, Boffetta P and La Vecchia C: Occupational exposures to polycyclic aromatic hydrocarbons and respiratory and urinary tract cancers: An updated systematic review and a meta-analysis to 2014. Arch Toxicol. 88:1479–1490. 2014. View Article : Google Scholar : PubMed/NCBI
15	Burstyn I, Boffetta P, Heederik D, et al: Mortality from obstructive lung diseases and exposure to polycyclic aromatic hydrocarbons among asphalt workers. Am J Epidemiol. 158:468–478. 2003. View Article : Google Scholar : PubMed/NCBI
16	Boffetta P, Burstyn I, Partanen T, et al: Cancer mortality among European asphalt workers: An international epidemiological study. I. Results of the analysis based on job titles. Am J Ind Med. 43:18–27. 2003. View Article : Google Scholar
17	Iizasa T, Momiki S, Bauer B, Caamano J, Metcalf R, Lechner J, Harris CC and Klein-Szanto AJ: Invasive tumors derived from xenotransplanted, immortalized human cells after in vivo exposure to chemical carcinogens. Carcinogenesis. 14:1789–1794. 1993. View Article : Google Scholar : PubMed/NCBI
18	Melchiori A, Colacci A, Lollini PL, De Giovanni C, Carlone S, Grilli S, Parodi S and Albini A: Induction of invasive and experimental metastasis potential in BALB/c 3T3 cells by benzo(a)pyrene transformation. Invasion Metastasis. 12:1–11. 1992.PubMed/NCBI
19	Ueng TH, Chang YL, Tsai YY, Su JL, Chan PK, Shih JY, Lee YC, Ma YC and Kuo ML: Potential roles of fibroblast growth factor-9 in the benzo(a)pyrene-induced invasion in vitro and the metastasis of human lung adenocarcinoma. Arch Toxicol. 84:651–660. 2010. View Article : Google Scholar : PubMed/NCBI
20	Yoshino I, Kometani T, Shoji F, Osoegawa A, Ohba T, Kouso H, Takenaka T, Yohena T and Maehara Y: Induction of epithelial-mesenchymal transition-related genes by benzo[a]-pyrene in lung cancer cells. Cancer. 110:369–374. 2007. View Article : Google Scholar : PubMed/NCBI
21	Wang Y, Zhai W, Wang H, Xia X and Zhang C: Benzo(a)pyrene promotes A549 cell migration and invasion through up-regulating Twist. Arch Toxicol. May 22–2014.(Epub ahead of print).
22	Martos I, Ferreres F and Tomás-Barberán FA: Identification of flavonoid markers for the botanical origin of Eucalyptus honey. J Agric Food Chem. 48:1498–1502. 2000. View Article : Google Scholar : PubMed/NCBI
23	Martos I, Ferreres F, Yao L, D’Arcy B, Caffin N and Tomás-Barberán FA: Flavonoids in monospecific eucalyptus honeys from Australia. J Agric Food Chem. 48:4744–4748. 2000. View Article : Google Scholar : PubMed/NCBI
24	Yao L, Jiang Y, D’Arcy B, Singanusong R, Datta N, Caffin N and Raymont K: Quantitative high-performance liquid chromatography analyses of flavonoids in Australian Eucalyptus honeys. J Agric Food Chem. 52:210–214. 2004. View Article : Google Scholar : PubMed/NCBI
25	Geraets L, Moonen HJ, Brauers K, Wouters EF, Bast A and Hageman GJ: Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells. J Nutr. 137:2190–2195. 2007.PubMed/NCBI
26	Hsu YL, Uen YH, Chen Y, Liang HL and Kuo PL: Tricetin, a dietary flavonoid, inhibits proliferation of human breast adenocarcinoma mcf-7 cells by blocking cell cycle progression and inducing apoptosis. J Agric Food Chem. 57:8688–8695. 2009. View Article : Google Scholar : PubMed/NCBI
27	Hsu YL, Hou MF, Tsai EM and Kuo PL: Tricetin, a dietary flavonoid, induces apoptosis through the reactive oxygen species/c-Jun NH2-terminal kinase pathway in human liver cancer cells. J Agric Food Chem. 58:12547–12556. 2010. View Article : Google Scholar : PubMed/NCBI
28	Casimiro S, Mohammad KS, Pires R, et al: RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One. 8:e631532013. View Article : Google Scholar : PubMed/NCBI
29	Krishnan V, Vogler EA, Sosnoski DM and Mastro AM: In vitro mimics of bone remodeling and the vicious cycle of cancer in bone. J Cell Physiol. 229:453–462. 2014. View Article : Google Scholar
30	Manenti G, Peissel B, Gariboldi M, et al: A cancer modifier role for parathyroid hormone-related protein. Oncogene. 19:5324–5328. 2000. View Article : Google Scholar : PubMed/NCBI
31	Wu X, Liu T, Fang O, Leach LJ, Hu X and Luo Z: miR-194 suppresses metastasis of non-small cell lung cancer through regulating expression of BMP1 and p27(kip1). Oncogene. 33:1506–1514. 2014. View Article : Google Scholar
32	Hernández I, Moreno JL, Zandueta C, Montuenga L and Lecanda F: Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer. Oncogene. 29:3758–3769. 2010. View Article : Google Scholar : PubMed/NCBI
33	Sone S and Yano S: Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone. Cancer Metastasis Rev. 26:685–689. 2007. View Article : Google Scholar : PubMed/NCBI
34	Weilbaecher KN, Guise TA and McCauley LK: Cancer to bone: A fatal attraction. Nat Rev Cancer. 11:411–425. 2011. View Article : Google Scholar : PubMed/NCBI
35	Coleman RE and McCloskey EV: Bisphosphonates in oncology. Bone. 49:71–76. 2011. View Article : Google Scholar : PubMed/NCBI
36	Hiraki A, Ueoka H, Bessho A, Segawa Y, Takigawa N, Kiura K, Eguchi K, Yoneda T, Tanimoto M and Harada M: Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia. Cancer. 95:1706–1713. 2002. View Article : Google Scholar : PubMed/NCBI
37	Hsu YL, Tsai EM, Hou MF, Wang TN, Hung JY and Kuo PL: Obtusifolin suppresses phthalate esters-induced breast cancer bone metastasis by targeting parathyroid hormone-related protein. J Agric Food Chem. 62:11933–11940. 2014. View Article : Google Scholar : PubMed/NCBI
38	Shen X and Falzon M: PTH-related protein upregulates integrin alpha6beta4 expression and activates Akt in breast cancer cells. Exp Cell Res. 312:3822–3834. 2006. View Article : Google Scholar : PubMed/NCBI
39	Kitazawa S and Kitazawa R: RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol. 198:228–236. 2002. View Article : Google Scholar : PubMed/NCBI
40	Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ and Gillespie MT: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140:4451–4458. 1999.PubMed/NCBI
41	Yasuda H, Shima N, Nakagawa N, et al: A novel molecular mechanism modulating osteoclast differentiation and function. Bone. 25:109–113. 1999. View Article : Google Scholar : PubMed/NCBI
42	Jansen ID, Vermeer JA, Bloemen V, Stap J and Everts V: Osteoclast fusion and fission. Calcif Tissue Int. 90:515–522. 2012. View Article : Google Scholar : PubMed/NCBI
43	Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
44	Jun AY, Kim HJ, Park KK, Son KH, Lee DH, Woo MH and Chung WY: Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts. Invest New Drugs. 32:1–13. 2014. View Article : Google Scholar
45	Bendre MS, Margulies AG, Walser B, et al: Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res. 65:11001–11009. 2005. View Article : Google Scholar : PubMed/NCBI
46	Hsu YL, Hung JY, Ko YC, Hung CH, Huang MS and Kuo PL: Phospholipase D signaling pathway is involved in lung cancer-derived IL-8 increased osteoclastogenesis. Carcinogenesis. 31:587–596. 2010. View Article : Google Scholar : PubMed/NCBI
47	Lewiecki EM: Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs. 71:791–814. 2011. View Article : Google Scholar : PubMed/NCBI
48	Papapetrou PD: Bisphosphonate-associated adverse events. Hormones (Athens). 8:96–110. 2009. View Article : Google Scholar